Company Active LTD

Company profile

Alchemab Therapeutics Ltd

Alchemab Therapeutics | Harnessing the Power of the Immune System

Alchemab Therapeutics Ltd is a UK company with status active founded in 2019.

CRN
12156844
Founded
2019
Age
6

Overview

Legal name
ALCHEMAB THERAPEUTICS LTD
Region
Unknown
Registered address
EAST SIDE OFFICE 1.02
KINGS CROSS
LONDON
UNITED KINGDOM
N1C 4AX
Insolvency history
No

Company events

Reference milestones and recent Companies House filing stream events.

12 events
12 Dec
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

30 Sep
2026

Accounts due

Accounts Due

Next accounts due date

19 Jun
2026

Appoint Person Director Company With Name Date

Officers

AP01 | Transaction MzUyNzM0MzQ2OWFkaXF6a2N4

Published 19 Jun 2026 14:23

19 Jun
2026

Termination Director Company With Name Termination Date

Officers

TM01 | Transaction MzUyNzM0MTg0NWFkaXF6a2N4

Published 19 Jun 2026 14:20

19 Jun
2026

Termination Director Company With Name Termination Date

Officers

TM01 | Transaction MzUyNzMzODY5MmFkaXF6a2N4

Published 19 Jun 2026 13:35

28 Nov
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Dec
2024

Accounts filed

Accounts

Last accounts made up date

18 Oct
2024

Capital Allotment Shares

Capital

SH01 | Transaction MzQ0MDA4MjkzMmFkaXF6a2N4

Published 18 Oct 2024 02:11

16 Sep
2024

Appoint Person Director Company With Name Date

Officers

AP01 | Transaction MzQzNTYzNjU5MGFkaXF6a2N4

Published 16 Sep 2024 08:52

12 Sep
2024

Termination Director Company With Name Termination Date

Officers

TM01 | Transaction MzQzNTUyODE0NmFkaXF6a2N4

Published 12 Sep 2024 16:18

28 Aug
2024

Resolution

Resolution

RESOLUTIONS | Transaction WURBMk1LWDVhZGlxemtjeA | Paper/PDF filed

Published 29 Aug 2024 07:00

14 Aug
2019

Incorporated

Inception

Company registered at Companies House

Public funding

2 awards
First funded
2021
Funded years
2021, 2022
Age at first award
1 years

Projects

2022 Collaborative R&D Lead participant

Pre-clinical Development of novel ‘self’-antibodies for disease modification in Huntington’s Disease

1 Dec 2022 to 29 Feb 2024

Awarded
£1,350,188
Total cost £2,250,313

Alchemab Therapeutics has a new way of approaching drug discovery by focussing on what keeps people well, sometimes against the odds. All of us produce a vast repertoire of different antibodies as part of our usual immune responses to fend off pathogens and to help the body maintain its health status. We believe that some individuals are able to use this ...

2021 Collaborative R&D Lead participant

Novel protective 'self'-antibodies for disease modification in Huntington’s Disease

1 Mar 2021 to 31 Oct 2022

Awarded
£988,266
Total cost £1,411,808

Alchemab Therapeutics has a new way of approaching drug discovery by focussing on what keeps people well, sometimes against the odds. All of us produce a vast repertoire of different antibodies as part of our usual immune responses to fend off pathogens and to help the body maintain its health status. We believe that some individuals are able to use this ...

Product types

Collaborative R&D